Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Angela A. Vitali"'
Autor:
Georgia A. Corner, Vinochani Pillay, Richard J. Simpson, Hong Ji, Sze Ting Lee, Robert Speirs, Andrew M. Scott, Kai Stühler, Terrance Grant Johns, Angela A. Vitali, David W. Greening, Carmel Murone, Angela Rigopoulos, John M. Mariadason
An important mediator of tumorigenesis, the epidermal growth factor receptor (EGFR) is expressed in almost all non-transformed cell types, associated with tumor progression, angiogenesis and metastasis. The significance of the EGFR as a cancer therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e789ad4f4e4dd608a8a217a32644745b
Autor:
Sameer A Greenall, Ermanno Gherardi, Zhanqi Liu, Jacqueline F Donoghue, Angela A Vitali, Qian Li, Roger Murphy, Luisa Iamele, Andrew M Scott, Terrance G Johns
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34658 (2012)
The c-MET receptor has a function in many human cancers and is a proven therapeutic target. Generating antagonistic or therapeutic monoclonal antibodies (mAbs) targeting c-MET has been difficult because bivalent, intact anti-Met antibodies frequently
Externí odkaz:
https://doaj.org/article/3215250fd70647869da99e78f2d5188a
Autor:
Lorraine K. Webster, Terrance Grant Johns, Maureen Nerrie, Andrew M. Scott, Janet Weinstock, Antony W. Burgess, Roger Murphy, Francesca Walker, G. McLachlan, Alexander Levitzki, M.M. Doherty, Angela A. Vitali, Edouard C. Nice, Andrew G. Ellis
Publikováno v:
Biochemical Pharmacology. 71:1422-1434
The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is a potent and specific inhibitor of EGFR tyrosine kinase whose favourable preclinical profile supports progression towards clinical trials. Microphysiometric evaluation revealed a
Autor:
A.H. Beth, Kristin B. Whitson, Austin J. McCoy, Monica Red-Brewer, Francesca Walker, James V. Staros, Terrance Grant Johns, Stefanie R. Whitson, Angela A. Vitali
Publikováno v:
Biochemistry. 44:14920-14931
We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). Our previous study showed that the population of cell-surface expressed EGFRs in A431 cells, a human epidermoid carcinoma cell line, is
Publikováno v:
Neuro-Oncology. 6:307-400
Autor:
Marc G. Achen, Richard J. Simpson, Teresa Domagala, Kari Alitalo, Kaye L. Stenvers, Steven A. Stacker, Sally Roufail, Carol Caesar, Angela A. Vitali, Edouard C. Nice, Terhi Karpanen, Robert L. Moritz
Publikováno v:
Journal of Biological Chemistry. 274:32127-32136
Vascular endothelial growth factor-D (VEGF-D) binds and activates the endothelial cell tyrosine kinase receptors VEGF receptor-2 (VEGFR-2) and VEGF receptor-3 (VEGFR-3), is mitogenic for endothelial cells, and shares structural homology and receptor
Autor:
Tanja Veikkola, Lyn M. Wise, Stephen B. Fleming, Andrew A. Mercer, Taija Makinen, Loreen J. Savory, Carol Caesar, Kari Alitalo, Steven A. Stacker, Angela A. Vitali
Publikováno v:
Proceedings of the National Academy of Sciences. 96:3071-3076
Orf virus, a member of the poxvirus family, produces a pustular dermatitis in sheep, goats, and humans. The lesions induced after infection with orf virus show extensive proliferation of vascular endothelial cells, dilation of blood vessels and derma
Autor:
Eola Kukk, Michael Jeltsch, Marc G. Achen, Angela A. Vitali, Kari Alitalo, Steven A. Stacker, Taija Makinen, Andrew F. Wilks
Publikováno v:
Proceedings of the National Academy of Sciences. 95:548-553
We have identified a member of the VEGF family by computer-based homology searching and have designated it VEGF-D. VEGF-D is most closely related to VEGF-C by virtue of the presence of N- and C-terminal extensions that are not found in other VEGF fam
Autor:
Zhanqi Liu, Luisa Iamele, Angela A. Vitali, Qian Li, Sameer A. Greenall, Jacqueline F. Donoghue, Roger Murphy, Ermanno Gherardi, Andrew M. Scott, Terrance Grant Johns
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 4, p e34658 (2012)
PLoS ONE, Vol 7, Iss 4, p e34658 (2012)
The c-MET receptor has a function in many human cancers and is a proven therapeutic target. Generating antagonistic or therapeutic monoclonal antibodies (mAbs) targeting c-MET has been difficult because bivalent, intact anti-Met antibodies frequently
Autor:
Andrew M. Scott, Angela A. Vitali, Diana X. Cao, Webster K. Cavenee, Frank B. Furnari, Rushika M. Perera, Sonja C. Vernes, Terrance Grant Johns
Publikováno v:
Clinical Cancer Research
Purpose: Factors affecting the efficacy of therapeutic monoclonal antibodies (mAb) directed to the epidermal growth factor receptor (EGFR) remain relatively unknown, especially in glioma. Experimental Design: We examined the efficacy of two EGFR-spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc4025ff789daf42feb39b1096921f23
https://hdl.handle.net/11858/00-001M-0000-0012-1379-D11858/00-001M-0000-0012-137A-B
https://hdl.handle.net/11858/00-001M-0000-0012-1379-D11858/00-001M-0000-0012-137A-B